Welcome to Cymbalta News
Cymbalta News is commited to providing news and information about Cymbalta, the new SSRNI from Eli Lilly.
Cymbalta works to treat more than one condition. Cymbalta has been approved by the FDA for both the treatment of depression and the management of pain associated with diabetic peripheral neuropathy. Cymbalta (an SSNRI) targets two chemicals, serotonin and norepinephrine, that are believed to play a role in how the brain and body affect mood and pain.
Cymbalta and Depression
Cymbalta offers relief for the emotional and physical symptoms associated with depression. It may help restore the balance of two naturally occurring chemicals in the brain and body that experts believe are related to major depressive disorder.
Many antidepressants target one chemical, serotonin. Cymbalta also targets a second chemical, norepinephrine. In clinical trials, Cymbalta was proven effective in treating depression, both its emotional and physical symptoms.
In clinical studies, many people began to show improvement in emotional and physical symptoms as early as one to four weeks.
Cymbalta for Pain Relief of DPNP
Cymbalta has been approved by the FDA for the management of diabetic peripheral neuropathic pain (DPNP).
Cymbalta is an FDA-approved treatment for the management of pain associated with diabetic peripheral neuropathy. Cymbalta doesn't undo or stop nerve damage, and it can't make diabetes go away.
Cymbalta acts as a pain reducer due to its effect on two naturally occurring chemicals in the central nervous system, serotonin and norepinephrine.
Many people suffering from diabetic peripheral neuropathic pain (DPNP) can receive significant pain relief in as little as one week. Patients on a study felt improvement during the entire length of the 12-week study. Patients also felt significant pain relief at night in as little as one week, with continued improvement over the suration of the study.